Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1994-11-3
|
pubmed:abstractText |
Serum prostate-specific antigen (PSA) levels following definitive radiation for prostate cancer are increasingly recognized as the most sensitive means to monitor disease status. However, beyond general agreement that patients fare poorly when posttreatment PSA levels fail to normalize, many questions relative to postirradiation PSA remain unanswered. This study evaluates the potential prognostic value of postirradiation PSA in a large cohort of patients followed with serial PSA determinations.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0360-3016
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
30
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-87
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7523340-Aged,
pubmed-meshheading:7523340-Aged, 80 and over,
pubmed-meshheading:7523340-Humans,
pubmed-meshheading:7523340-Male,
pubmed-meshheading:7523340-Middle Aged,
pubmed-meshheading:7523340-Multivariate Analysis,
pubmed-meshheading:7523340-Prognosis,
pubmed-meshheading:7523340-Prostate-Specific Antigen,
pubmed-meshheading:7523340-Prostatic Neoplasms
|
pubmed:year |
1994
|
pubmed:articleTitle |
Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
|
pubmed:affiliation |
Department of Clinical Radiotherapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|